- Home
- NSA vs GPCR Comparison
NSA vs GPCR Comparison
Compare NSA & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSA | GPCR |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | 1458 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | NSA | GPCR |
|---|---|---|
| Price | $44.77 | $53.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $34.38 | ★ $103.17 |
| AVG Volume (30 Days) | 676.6K | ★ 842.4K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.39 | N/A |
| P/E Ratio | $56.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.43 | $15.80 |
| 52 Week High | $46.47 | $94.90 |
Technical Indicators
Market Signals| Indicator | NSA | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 64.30 |
| Support Level | $41.07 | $36.11 |
| Resistance Level | $46.47 | $57.23 |
| Average True Range (ATR) | 0.93 | 2.65 |
| MACD | -0.13 | 0.44 |
| Stochastic Oscillator | 40.17 | 70.94 |
Price Performance
Historical ComparisonAbout NSA National Storage Affiliates Trust of Beneficial Interest
National Storage Affiliates Trust Trust is a real estate investment trust. The company owns, operates, and acquires self-storage properties located within the metropolitan statistical areas throughout the United States. With the help of property management platform, the company manages and controls the day-to-day operations and affairs of consolidated properties and unconsolidated real estate ventures under the iStorage, SecurCare, RightSpace, Northwest and Move It brands.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.